- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02013700
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) (AETHER)
A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Idiopathic Pulmonary Fibrosis (IPF) is a progressive and debilitating lung disease characterized by interstitial fibrosis with decreasing lung volumes and pulmonary insufficiency eventually resulting in death. Patients with Idiopathic Pulmonary Fibrosis (IPF) typically present with complaints of sub acutely progressive dyspnea and non-productive cough, often accompanied by digital clubbing. Due to the insidious onset of symptoms, however, most patients are diagnosed at late stages of the disease after significant fibrosis has occurred. Physical exam is characterized by hypoxemia, "dry" inspiratory crackles on auscultation, and occasional digital clubbing (6). Pulmonary function tests (PFTs) usually reveal restrictive lung physiology with progressive decline of forced vital capacity (FVC), diffusion capacity (DLCO) and six-minute walk distances. Diagnosis is established by the pathologic finding of usual interstitial pneumonia (with sub epithelial fibroblastic foci) by open lung biopsy (7), and/or by high resolution CT (HRCT) demonstrating the characteristic findings of peripheral/basal sub pleural reticulonodular changes with fibrosis, honeycombing, and traction bronchiectasis (8, 9).
The prognosis for patients with Idiopathic Pulmonary Fibrosis (IPF) is uniformly poor. The natural history of the disease is characterized by inexorable progressive decline interspersed with "exacerbations" or periods of accelerated disease which are often fatal (5). There are no FDA approved treatment options for patients with Idiopathic Pulmonary Fibrosis (IPF) and thus no standard of care. In cases of patients under the age of 60 with limited comorbid disease, lung transplant may be offered. Patients with Idiopathic Pulmonary Fibrosis (IPF) receive empiric treatment, supportive care alone, and more recently, are offered enrollment in clinical trials.
The pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) is characterized by epithelial cell injury and activation with interstitial inflammation, fibroblast proliferation with extracellular matrix collagen deposition, and eventual loss of function. Because mesenchymal stem cells are known to home to sites of injury, inhibit inflammation, and contribute to epithelial tissue repair, their use has been suggested as a novel therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Interdisciplinary Stem Cell Institute / University of Miami
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent.
- Subjects age equal to or greater than 40 and equal to or less than 90 years at the time of signing the Informed Consent Form.
- Have a clinical diagnosis of Idiopathic Pulmonary Fibrosis (IPF) prior to screening
- Forced vital capacity (FVC) ≥ 50% predicted and diffusing capacity (DLCO) ≥30% (corrected for hemoglobin but not alveolar volume).
- RVSP equal to or less than 50 mmHg, as documented by Doppler echo or right heart catheterization.
- Female subjects must be surgically sterile or post-menopausal (greater than 1 year).
Exclusion Criteria:
- HRCT and/or surgical lung biopsy results inconsistent with the diagnosis of IPF.
- Infiltrative lung disease of any type other than Idiopathic Pulmonary Fibrosis (IPF), lungs disease related to fibrogenic agents, toxins, drugs or other exposures, granulomatous lung disease, pulmonary vascular disease, or known connective tissue disease.
- Inability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform pulmonary function tests or high resolution CT (HRCT), undergo blood draws, read and respond to questionnaires.
- Currently receiving (or received within four weeks of screening) any medication, treatment, or experimental agents for the treatment of Idiopathic Pulmonary Fibrosis (IPF), except for patients receiving non drug therapies will include oxygen saturation therapy (oxygen supplementation) and pulmonary rehabilitation.
- Active listing (or expected future listing) for transplant of any organ.
- Clinically important abnormal screening laboratory values, including but not limited to: hemoglobin <8 g/dl, white blood cell count <3000/mm3, platelets <80,000/mm3, INR > 1.5, aspartate transaminase, alanine transaminase, or alkaline phosphatase > 3 times upper limit of normal, total bilirubin > 1.5 mg/dl.
- Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. Including, but not limited to: HIV, advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, or cardiac revascularization within the last six months, or severe obstructive ventilatory defect.
- Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
- Have known allergies to penicillin or streptomycin.
- Be an organ transplant recipient.
- Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
- Have a non-pulmonary condition that limits lifespan to less than 1 year.
- Have a history of drug or alcohol abuse within the past 24 months.
- Be serum positive for Human immunodeficiency virus (HIV), hepatitis BsAg or Viremic hepatitis C.
- Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
- Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.
- Female subjects must have a FSH less than 25.8 IU/L
- Subject with hypersensitivity to dimethyl sulfoxide (DMSO)
- Saturated oxygen (SpO2 of less than 93% (room air [sea level] at rest). SpO2 of less than 88% (room air [>5,000 feet above sea level (1524 meters) at rest).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 20 million hMSCs
Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
|
|
Placebo Comparator: Placebo
Patients will receive a matched placebo delivered via peripheral intravenous infusion
|
The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
|
Experimental: 100 million hMSCs
Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
|
|
Experimental: 200 million hMSCs
Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety and tolerability of intravenous allo hMSCs in patients with Idiopathic Pulmonary Fibrosis (IPF).
Time Frame: One month post infusion
|
Safety (Primary): Incidence (one month post infusion) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.
|
One month post infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
- To explore effects of allo hMSCs on lung function: forced vital capacity (FVC).
Time Frame: Participants will be followed from 12 weeks to an expected average of 60 weeks following infusion.
|
- Difference in absolute decline of forced vital capacity (FVC) percent predicted.
|
Participants will be followed from 12 weeks to an expected average of 60 weeks following infusion.
|
To explore effects of allogenic human mesenchymal stem cells on symptom related quality of life.
Time Frame: Participants will be followed from 4 weeks to an expected average of 60 weeks following infusion.
|
- Quality of Life endpoint tools to be used include: University of California San Diego-Shortness of breath (UCSD-SOBQ), short form - 36 (SF-36), and St. George's respiratory questionnaire (SGRQ) questionnaires.
|
Participants will be followed from 4 weeks to an expected average of 60 weeks following infusion.
|
Difference in frequency of acute exacerbations of Idiopathic Pulmonary Fibrosis (IPF)
Time Frame: 4 weeks following infusion
|
Defined as:
|
4 weeks following infusion
|
Death from any cause.
Time Frame: 60 weeks.
|
Participants will be followed for the duration of the trial, which is an expected average of 60 weeks.
|
60 weeks.
|
To explore effects of allogenic human mesenchymal stem cells on lung function: Diffusing Capacity (DLCO)
Time Frame: Participants will be followed from 12 weeks to an expected average of 60 weeks following infusion.
|
- Difference in absolute decline of Diffusing capacity (DLCO).
|
Participants will be followed from 12 weeks to an expected average of 60 weeks following infusion.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marilyn K. Glassberg, MD, University of Miami
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20120946
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis (IPF)
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Metagone Biotech Inc.CompletedIdiopathic Pulmonary Fibrosis (IPF)Taiwan
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
University of Colorado, DenverWithdrawn
Clinical Trials on Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)
-
Joshua M HareThe Emmes Company, LLCCompletedMyocardial Infarction | Chronic Ischemic Left Ventricular DysfunctionUnited States
-
Joshua M HareNational Heart, Lung, and Blood Institute (NHLBI)CompletedDiabetes Mellitus, Type 2United States
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
Joshua M HareWithdrawnCrohn's Disease | Stem Cells | Fistulizing Crohn's DiseaseUnited States
-
Longeveron Inc.TerminatedHypoplastic Left Heart SyndromeUnited States
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)RecruitingDiabetes Mellitus | Ischemic Heart DiseaseUnited States
-
Joshua M HareTerminatedTreatment Resistant DepressionUnited States
-
Joshua M HareThe University of Texas Health Science Center, Houston; United States Department...RecruitingNon-ischemic Dilated CardiomyopathyUnited States
-
Stemedica Cell Technologies, Inc.University of California, San Diego; Mercy Gilbert Medical Center at AZ; Chandler... and other collaboratorsCompletedIschemic StrokeUnited States
-
Marilyn GlassbergThe Marcus FoundationTerminated